Developing a Patient-Centered Counseling Tool for Resuming Sexual Activity After Pelvic Reconstructive Surgery: A Qualitative and Cognitive Interview Approach
Posted inOB/GYN & Women's Health Plastic Surgery Urology

Developing a Patient-Centered Counseling Tool for Resuming Sexual Activity After Pelvic Reconstructive Surgery: A Qualitative and Cognitive Interview Approach

A novel, evidence-based counseling tool was developed to guide patients in safely resuming sexual activity after pelvic reconstructive surgery. The tool integrates patient perspectives and expert input, addressing safety, discomfort, and recovery expectations.
Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis
Posted inClinical Updates news Oncology Urology

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients ineligible for cisplatin, with manageable safety.
Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial
Posted innews Oncology Urology

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiotherapy alone, with limited toxicity.
Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy
Posted inClinical Updates Oncology Specialties Urology

Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy

The GROUQ-PCS 9 trial demonstrates that adding stereotactic body radiotherapy to standard androgen deprivation therapy and enzalutamide significantly prolongs radiographic progression-free survival in oligometastatic castration-resistant prostate cancer with manageable toxicity.
Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223
Posted inOncology Urology

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223

The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metastases, with manageable toxicity and importance of bone-protecting agents.